Difference between revisions of "Lung Density Biomarker Ctte"

From QIBA Wiki
Jump to: navigation, search
m (Recent Meetings/Call Summaries)
(Recent Meetings/Call Summaries)
Line 19: Line 19:
 
*[[Media:03 28 2018 QIBA CT Lung Density BC Call Summary-FINAL.pdf|03.28.2018 QIBA Lung Density Biomarker Committee Call Summary]]
 
*[[Media:03 28 2018 QIBA CT Lung Density BC Call Summary-FINAL.pdf|03.28.2018 QIBA Lung Density Biomarker Committee Call Summary]]
 
*[[Media:02 28 2018 QIBA CT Lung Density BC Call Summary-FINAL.pdf|02.28.2018 QIBA Lung Density Biomarker Committee Call Summary]]
 
*[[Media:02 28 2018 QIBA CT Lung Density BC Call Summary-FINAL.pdf|02.28.2018 QIBA Lung Density Biomarker Committee Call Summary]]
*[[Media:01 31 2018 QIBA CT Lung Density BC Call Summary-FINAL.pdf|01.31.2018 QIBA Lung Density Biomarker Committee Call Summary]]
 
*[[Media:01 17 2018 QIBA CT Lung Density BC Call Summary-FINAL.pdf|01.17.2018 QIBA Lung Density Biomarker Committee Call Summary]]
 
 
*[[Media:12 20 2017 QIBA CT Lung Density BC Call Summary-FINAL.pdf|12.20.2017 QIBA Lung Density Biomarker Committee Call Summary]]
 
*[[Media:10 25 2017 QIBA CT Lung Density BC Call Summary-FINAL.pdf|10.25.2017 QIBA Lung Density Biomarker Committee Call Summary]]
 
*[[Media:10 11 2017 QIBA CT Lung Density BC Call Summary-FINAL.pdf|10.11.2017 QIBA Lung Density Biomarker Committee Call Summary]]
 
*[[Media:09 13 2017 QIBA CT Lung Density BC Call Summary-FINAL.pdf|09.13.2017 QIBA Lung Density Biomarker Committee Call Summary]]
 
  
 
'''''[[Lung Density/COPD BC Call Summaries Archive]]'''''
 
'''''[[Lung Density/COPD BC Call Summaries Archive]]'''''

Revision as of 14:22, 4 June 2018

Co-chairs: Sean Fain, PhD; Matthew Fuld, PhD; David Lynch, MD
Secretary: Julie Lisiecki

Scope

Scope: Quantitative CT lung densitometry and morphology for COPD and related diseases.

Initial Objectives:

  • Characterize the precision and accuracy of phenotyping and progression measurements in emphysema and asthma.
This is an essential effort to classify phenotype and assess longitudinal changes as medically meaningful surrogates for health status.
  • Compare the sensitivity of CT measurements to spirometry and other accepted measures.
This will be necessary in order to determine if Progressive Disease can be detected significantly sooner with quantitative imaging techniques than with currently accepted methods.

Recent Meetings/Call Summaries

Lung Density/COPD BC Call Summaries Archive

Profile Development

Status - <summarize current status>

Archive - Lung Density

Protocol Development Activities


Groundwork Activities

Validate key concepts and answer key questions needed to write the Profiles and demonstrate their effectiveness.

  • Phantom project


Working Documents


Reference Documents


Round 2 of QIBA Funded Projects